Highest-materiality recent filing
ISCO agrees to sell Lifeline Cell Technology to ATCC for $25M in cash
Purchase price $25M, subject to net working capital, cash, and debt adjustments; closing expected Q3 2026.
Stockholders elect four directors at International Stem Cell annual meeting
Andrey Semechkin and Russell Kern elected directors by Series D Preferred Stock with 2,457,143 votes each.
International Stem Cell reports annual meeting voting results
All four director nominees elected: Semechkin and Kern (Series D), Wright and Maier (all shares) with 7.77M votes each.
International Stem Cell extends CEO loan of $2.5M to Sept 2026
Extended maturity of $2.5M promissory note from CEO Andrey Semechkin from Sept 15, 2025 to Sept 15, 2026.
International Stem Cell extends CEO's $2.7M loan maturity to Sept 2025 after repaying $200k
CEO Dr. Andrey Semechkin loan of $2.9M extended; $200k repaid, new $2.7M unsecured note issued.
International Stem Cell extends $2.9M CEO loan maturity to Sept 2024
CEO Andrey Semechkin extended $2.9M promissory note maturity from Sept 15, 2023 to Sept 15, 2024.
International Stem Cell Corp holds annual meeting, elects four directors
Shareholders elected directors Andrey Semechkin and Russell Kern (Series D Preferred holders) each with 2,457,143 for, 0 withheld.
International Stem Cell extends $2.9M CEO loan maturity to September 2023
Principal $2.9M from CEO Andrey Semechkin; maturity extended from Mar 15 to Sep 15, 2023.
CEO extends $2.9M loan maturity to March 2023 at 4.5% interest
On Sep 15, 2022, International Stem Cell Corp. extended maturity of $2.9M loan from CEO Andrey Semechkin to Mar 15, 2023.
Annual meeting results: directors elected, say-on-pay approved
Andrey Semechkin and Russell Kern elected by Series D Preferred Stock holders (2,457,143 votes each).
Dr. Russell Kern appointed principal financial officer effective April 25, 2022.
International Stem Cell extends $2.9M CEO loan maturity to Sept 15, 2022
Extended maturity of $2.9M promissory note from CEO Andrey Semechkin to Sept 15, 2022 (was Mar 15, 2022).
International Stem Cell Corp's CFO Sophia Garnette resigns effective April 1, 2022
Sophia Garnette, Principal Financial Officer and VP of Legal Affairs and Operations, submitted resignation.
International Stem Cell issues $2.9M promissory note to CEO Andrey Semechkin for working capital
Unsecured, non-convertible note for $2,900,000 issued to CEO/Co-Chairman on Jan 13, 2022.
International Stem Cell terminates headquarters lease early; no termination fee
Lease for 5950 Priestly Drive, Carlsbad, CA terminated effective no later than Dec 31, 2021.
International Stem Cell signs lease for new HQ in San Diego; related-party transaction
Lease covers 7,260 sq ft at 9745 Businesspark Ave, San Diego, consolidating Carlsbad and Oceanside offices.
On April 25, 2022, International Stem Cell Corporation, a Delaware corporation (the “Company”) appointed Dr. Russell Kern as its principal financial officer effective immediately.
On February 1, 2022, Sophia Garnette, Principal Financial Officer and VP of Legal Affairs and Operations of International Stem Cell Corporation (the "Company"), submitted her resignation, to be effective on April 1, 2022.
Max materiality 0.75 · Median 0.45 · Most common event debt